European Commission logo
English English
CORDIS - EU research results
CORDIS

Personalised blueprint intestinal health

Project description

Health-to-inflammatory bowel disease transition

Inflammatory bowel disease (IBD) is characterised by chronic inflammation in the lining of the colon and the small intestine. Currently, there are no biomarkers for predicting an individual’s risk to develop IBD. The EU-funded miGut-Health project proposes to address this unmet need by integrating disease models and molecular and clinical data alongside novel technologies. In addition, researchers will investigate the impact of diet and the gut microbiome on intestinal inflammation. Collectively, the project will help understand how healthy individuals may transition to IBD onset and engage patients in self-management through eHealth solutions.

Objective

The miGut-Health consortium aims to develop a personalized blueprint of intestinal health to predict and prevent inflammatory bowel disease. The overall goal is to deliver interdisciplinary solutions (molecular, nutritional, eHealth and patient engagement/empowerment level) for health promotion and disease prevention that would enable active patient engagement in health and self-care management.
Taking on this mission, miGut-Health pursues the following strategic goals:
- To integrate state-of-the-art omics (molecular, clinical, nutrition, social and environmental) for identification of actionable biomarkers, risk and health promoting factors linked to health-to-disease transition in the general population, IBD high risk persons, as well as IBD patients.
- To perform systems-level analyses of chronic inflammation by applying integrative models from omics and clinical data to predict risk for health-to-disease transition in IBD.
- To perform a proof-of-concept controlled clinical trial studying a nutrient elimination diet (here: gluten-free diet) and its impact on intestinal inflammation in IBD patients and high-risk individuals.
- To exploit the impact of microbiome-derived diet-associated metabolites on gut inflammation reversion and restoration of barrier integrity and function using an innovative co-culture system of primary human intestinal organoids and sorted immune cell subsets.
- To develop and apply novel technologies (sensors, mobile apps) to dynamically monitor individual nutrition as well as physical activity and principal health status.
- To implement a patient-centered approach for personalized health and self-care engagement targeted at IBD patients, individuals at risk for IBD and the general population as well as tools for health-care professionals.

Coordinator

UNIVERSITATSKLINIKUM SCHLESWIG-HOLSTEIN
Net EU contribution
€ 2 638 625,00
Address
Ratzeburger Allee 160
23562 Lübeck
Germany

See on map

Region
Schleswig-Holstein Schleswig-Holstein Lübeck, Kreisfreie Stadt
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 2 643 625,00

Participants (11)

Partners (1)